-

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, September 15, 2025, under the ticker symbol “SPRB” and CUSIP 85209E 208.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.

Contacts

Spruce Media
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
Katherine.Beach@inizioevoke.com
media@sprucebio.com

Spruce Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
investors@sprucebio.com

Industry:

Spruce Biosciences, Inc.

NASDAQ:SPRB
Release Versions
English

Contacts

Spruce Media
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
Katherine.Beach@inizioevoke.com
media@sprucebio.com

Spruce Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
investors@sprucebio.com

More News From Spruce Biosciences, Inc.

Spruce Biosciences Announces $50.0 Million Private Placement Financing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences Announces $50.0 Million Private Placement Financing...

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). “We are pleased t...

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2025 and provided corporate updates. “We remain steadfast in our efforts to advance TA-ERT as a potential first-to-market treatment for children diagnosed with Sanfilippo Syndrome T...
Back to Newsroom